Lupin Share Price: US mein diabetes drugs launch, Stock **1.60%** up! Kya ye badhega?

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorVihaan Mehta|Published at:
Lupin Share Price: US mein diabetes drugs launch, Stock **1.60%** up! Kya ye badhega?
Overview

Lupin Pharmaceuticals ke liye ek badi news hai! Unhe USFDA se approval mil gaya hai do diabetes generic drugs launch karne ke liye, jo ki Farxiga aur Xigduo XR ke generic versions hain. Is approval ke baad stock mein **1.60%** ka slight jump dikha hai.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Lupin ki US mein entry: Diabetes drugs ko mili USFDA green signal!

Lo bhaiyon, Lupin Pharmaceuticals ne US FDA se approval paa liya hai apni generic dapagliflozin aur dapagliflozin/metformin hydrochloride extended-release tablets launch karne ke liye. Ye drugs AstraZeneca ke Farxiga aur Xigduo XR ke bilkul bioequivalent hain. Matlab, ab Lupin bhi US ke massive anti-diabetic market mein apni jagah banane ki koshish karegi.

Kitna bada hai ye market aur competition?

US mein diabetes drugs ka market kaafi bada hai, lagbhag $33.80 billion ka. Lupin jin specific drugs ko target kar raha hai, unka market $10 billion se zyada ka hai. Lekin, yahan pehle se hi kaafi bhid hai. Alembic Pharmaceuticals aur Aurobindo Pharma jaise players bhi isi tarah ke generic drugs launch kar chuke hain. Lupin ka P/E ratio 22.8x hai, jo growth ki expectation dikhata hai, par generics market mein price pressure toh rehta hi hai.

Profit margins par pressure?

US mein generic drugs launch karna hamesha ek challenge hota hai. Competition itni zyada hai ki price kam rakhna padta hai, jisse profit margins par asar pad sakta hai. Waise toh Lupin ka North America business already unke total revenue ka 35-40% contribute karta hai, jo ek achha base hai. Lekin success pura supply chain aur speed par depend karta hai.

Analysts kya bol rahe hain?

Experts ki rai mili-juli hai. Kuch analysts ne 'Buy' rating di hai aur target price ₹2,460 ke aas paas rakha hai. Toh kuch, jaise UBS, ne 'Sell' rating di hai, kyunki unhe lagta hai ki US sales peak ho sakte hain. Lekin, Lupin ke recent Q3 FY26 results achhe rahe hain aur manufacturing sites bhi positive hain. Ab dekhna hai ki ye naye drugs company ke liye kitna revenue aur profit laate hain.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.